Dr. Aaron M. Etra, MD
Medical Oncology (Medical Oncology Physician)
- Medicare participating
At a glance
- Medical school
- Albert Einstein College of Medicine of Yeshiva University (2012)
- Years since graduation
- 14
- In the NPI registry since
- 2012
- Medicare patients seen, 2024
- 63
The NPI date is when this clinician registered for a National Provider Identifier, the billing number used on health claims. It is not a license, graduation or board-certification date. What an NPI is
Education and training
- 2012Medical school: Albert Einstein College of Medicine of Yeshiva University
- 2012Registered with an NPI (national billing number; not a license date)
Undergraduate school, residency, fellowship, licensing exams and board certification aren’t in public federal data. Board certification can be confirmed with the certifying board (ABMS member boards for MDs, AOA boards for DOs).
Specialties and state licenses
-
Medical Oncology Physician primary
NY license 279145
As reported to the NPI registry. To confirm a license is current, check the state medical board.
Where they work
Hospitals
- Mount Sinai Hospital New York, NY
- Mount Sinai West New York, NY
Medical groups
- Icahn School of Medicine at Mount Sinai (2,843 clinicians)
Hospitals this clinician lists with Medicare, and groups they bill Medicare through (Care Compare). Affiliation doesn’t mean they see patients at every location.
Medicare patients and services
- Medicare patients, 2024
- 63
- Services billed
- 388
- Patients’ average age
- 68
| Service | Times | Patients |
|---|---|---|
| Subsequent hospital care with moderate levelof medical decision making, if using time, at least 50 minutes | 165 | 38 |
| Established patient office or other outpatient visit, 40-54 minutes | 70 | 18 |
| Established patient office or other outpatient visit, 30-39 minutes | 26 | 14 |
Medicare fee-for-service only. CMS leaves out services billed for fewer than 11 patients. These figures describe a practice’s Medicare work; they aren’t a measure of quality.
Medicare prescriptions
| Drug | Prescriptions |
|---|---|
| Acyclovir Other prescribers in New York, NY | 77 |
| Jakafi (ruxolitinib phosphate) | 64 |
| Atovaquone | 43 |
| Rezurock (belumosudil mesylate) | 33 |
| Posaconazole | 32 |
| Valacyclovir (valacyclovir hcl) Other prescribers in New York, NY | 26 |
| Triamcinolone Acetonide Other prescribers in New York, NY | 25 |
| Penicillin V Potassium Other prescribers in New York, NY | 23 |
| Amlodipine Besylate Other prescribers in New York, NY | 21 |
| Prevymis (letermovir) | 20 |
Prescriptions filled under Medicare Part D, including refills. CMS leaves out drugs prescribed fewer than 11 times.
Payments from drug and device companies
In 2025, 6 companies reported 20 payments worth $798 in total to this clinician.
| National Marrow Donor Program | $300 |
|---|---|
| Merck Sharp & Dohme LLC | $176 |
| Kite Pharma, Inc. | $157 |
| Sanofi-aventis U.S. LLC | $61.50 |
| Daiichi Sankyo Inc. | $54.50 |
| Csl Behring | $50.00 |
| Food and Beverage | $448 |
|---|---|
| Compensation for services other than consulting (speaking, faculty) | $300 |
| Consulting Fee | $50.00 |
What the payments were for
| Company | What it was for | Amount |
|---|---|---|
| National Marrow Donor Program Jan 10, 2025 | Compensation for services other than consulting (speaking, faculty) | $250 |
| National Marrow Donor Program Jan 31, 2025 | Compensation for services other than consulting (speaking, faculty) | $50.00 |
| Csl Behring Jan 1, 2025 | Consulting Fee | $50.00 |
Each payment as the company reported it, with the products it named. Meals are counted in the totals above but not listed one by one.
From CMS Open Payments. A payment is not evidence of wrongdoing; many are for consulting, teaching or meals. Clinicians can review and dispute their records with CMS.
Industry-funded research
Named as a principal investigator on 2 industry-funded studies in 2025, from 1 companies. The companies reported $26,802 in research payments for these studies, mostly to the institutions running them.
- A Randomized, Multicenter, Phase III Trial of Tacrolimus/Methotrexate/Ruxolitinib versus Post-Transplant Cyclophosphamide/Tacrolimus/Mycophenolate Mofetil in Non-Myeloablative/Reduced Intensity Conditioning Allogeneic…
National Marrow Donor Program - Facilitating Activation of Study Trials (FAST)
National Marrow Donor Program
From CMS Open Payments research payments, where companies name up to five principal investigators per payment. Research payments usually go to hospitals, universities and research sites, not to the investigator personally. A payment is not evidence of wrongdoing.